| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yuki Fujiwara, Shunsuke Eguchi, Hiroki Murayama, Yuri Takahashi, Mitsutoshi Toda, Kota Imai, Kinsuke Tsud. Relationship between diet/exercise and pharmacotherapy to enhance the GLP-1 levels in type 2 diabetes. Endocrinology, diabetes & metabolism. vol 2. issue 3. 2020-09-30. PMID:31294084. |
consuming protein-rich food, avoiding saturated fatty acids and making small changes in eating habits such as eating slowly with longer mastication time can have a positive impact on the glp-1 secretion and insulin levels. |
2020-09-30 |
2023-08-13 |
Not clear |
| Liwei Ren, Qiaoli Cui, Wenjuan Liu, Liqian Wang, Yijing Liao, Ying Feng, Wanwan Sun, Yehong Yang, Zhaoyun Zhang, Tianru Jin, Gerald J Prud'homme, Lina Zhang, Yiming Li, Ying Leng, Qinghua Wan. Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice. Frontiers in physiology. vol 10. 2020-09-30. PMID:31404283. |
novel glp-1 analog supaglutide stimulates insulin secretion in mouse and human islet beta-cells and improves glucose homeostasis in diabetic mice. |
2020-09-30 |
2023-08-13 |
mouse |
| Xiaohui Feng, Haili Liu, Zhaoping Li, Arianna Carughi, Sheng G. Acute Effect of Pistachio Intake on Postprandial Glycemic and Gut Hormone Responses in Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance: A Randomized, Controlled, Crossover Study. Frontiers in nutrition. vol 6. 2020-09-30. PMID:31921879. |
impaired postprandial glucose, insulin, and glucagon-like peptide-1 (glp-1) responses have been reported in gestational diabetes mellitus (gdm) patients. |
2020-09-30 |
2023-08-13 |
Not clear |
| Xiaohui Feng, Haili Liu, Zhaoping Li, Arianna Carughi, Sheng G. Acute Effect of Pistachio Intake on Postprandial Glycemic and Gut Hormone Responses in Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance: A Randomized, Controlled, Crossover Study. Frontiers in nutrition. vol 6. 2020-09-30. PMID:31921879. |
in summary, isocaloric pistachio intake induced significantly lower postprandial glucose, insulin and gip but higher glp-1 levels compared to wwb. |
2020-09-30 |
2023-08-13 |
Not clear |
| Xiaohui Feng, Haili Liu, Zhaoping Li, Arianna Carughi, Sheng G. Acute Effect of Pistachio Intake on Postprandial Glycemic and Gut Hormone Responses in Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance: A Randomized, Controlled, Crossover Study. Frontiers in nutrition. vol 6. 2020-09-30. PMID:31921879. |
our data suggest pistachios are effective alternative to a low-fat, high-carbohydrate food to improve postprandial glucose, insulin, and glp-1 response in women with gdm and gigt. |
2020-09-30 |
2023-08-13 |
Not clear |
| Sultan Linjawi, Bruce W Bode, Louis B Chaykin, Jean-Pierre Courrèges, Yehuda Handelsman, Lucine M Lehmann, Abhishek Mishra, Richard W Simpso. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 8. issue 1. 2020-09-29. PMID:27943107. |
the efficacy of ideglira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a glp-1 receptor agonist and oral therapy: dual iii randomized clinical trial. |
2020-09-29 |
2023-08-13 |
Not clear |
| Srikanth Yandrapalli, Wilbert S Arono. Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus. Journal of thoracic disease. vol 9. issue 7. 2020-09-29. PMID:28840014. |
as t2dm or insulin resistance syndrome, cv disease, and hf and frequently coexistent, it would be interesting to design studies evaluating the combinations of glp-1 ras, sglt-2 inhibitors, and pioglitazone in t2dm patient at an elevated cv risk, and in non-diabetic patients with insulin resistance to study the possible cv protective role of these combinations. |
2020-09-29 |
2023-08-13 |
Not clear |
| Murad H Kheder, Simon R Bailey, Kevin J Dudley, Martin N Sillence, Melody A de Laa. Equine glucagon-like peptide-1 receptor physiology. PeerJ. vol 6. 2020-09-29. PMID:29404215. |
circulating concentrations of the incretin hormone, glucagon-like peptide-1 (glp-1) correlate with an increased insulin response to carbohydrate intake in animals with ems. |
2020-09-29 |
2023-08-13 |
Not clear |
| Murad H Kheder, Simon R Bailey, Kevin J Dudley, Martin N Sillence, Melody A de Laa. Equine glucagon-like peptide-1 receptor physiology. PeerJ. vol 6. 2020-09-29. PMID:29404215. |
the objectives were to determine (1) the tissue localisation of the eglp-1r, (2) the glp-1 secretory capacity of equine intestine in response to glucose and (3) whether glp-1 stimulated insulin secretion from isolated pancreatic islets can be attenuated. |
2020-09-29 |
2023-08-13 |
Not clear |
| Rodrigo Oliveira Moreira, Roberta Cobas, Raquel C Lopes Assis Coelh. Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? Diabetology & metabolic syndrome. vol 10. 2020-09-29. PMID:29636825. |
combination of basal insulin and glp-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? |
2020-09-29 |
2023-08-13 |
Not clear |
| Rodrigo Oliveira Moreira, Roberta Cobas, Raquel C Lopes Assis Coelh. Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? Diabetology & metabolic syndrome. vol 10. 2020-09-29. PMID:29636825. |
this article reviews the efficacy and safety of different strategies to initiate and intensify basal insulin, with focus on new fixed ratio combinations of basal insulin with glp-1 ras available for use in a single injection pen (insulin degludec/liraglutide and insulin glargine/lixisenatide). |
2020-09-29 |
2023-08-13 |
Not clear |
| Lei Zhang, Yang Ouyang, Huating Li, Li Shen, Yueqiong Ni, Qichen Fang, Guangyu Wu, Lingling Qian, Yunfeng Xiao, Jing Zhang, Peiyuan Yin, Gianni Panagiotou, Guowang Xu, Jianping Ye, Weiping Ji. Metabolic phenotypes and the gut microbiota in response to dietary resistant starch type 2 in normal-weight subjects: a randomized crossover trial. Scientific reports. vol 9. issue 1. 2020-09-29. PMID:30894560. |
acetate and early-phase insulin, c-peptide and glucagon-like peptide-1 (glp-1) secretion were increased, and the low-density lipoprotein cholesterol (ldl-c) and blood urea nitrogen (bun) levels were decreased after the rs intervention. |
2020-09-29 |
2023-08-13 |
mouse |
| Lei Zhang, Yang Ouyang, Huating Li, Li Shen, Yueqiong Ni, Qichen Fang, Guangyu Wu, Lingling Qian, Yunfeng Xiao, Jing Zhang, Peiyuan Yin, Gianni Panagiotou, Guowang Xu, Jianping Ye, Weiping Ji. Metabolic phenotypes and the gut microbiota in response to dietary resistant starch type 2 in normal-weight subjects: a randomized crossover trial. Scientific reports. vol 9. issue 1. 2020-09-29. PMID:30894560. |
these observations suggest that a daily intake of 40 g of rs is effective in modulating body fat, scfas, early-phase insulin and glp-1 secretion and the gut microbiota in normal-weight subjects. |
2020-09-29 |
2023-08-13 |
mouse |
| Shan Wan, Hui Su. Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK/STAT3 signaling pathway. Experimental and therapeutic medicine. vol 17. issue 5. 2020-09-29. PMID:30988739. |
glucagon-like peptide-1 (glp-1) is used to treat diabetes due to its beneficial role against insulin resistance. |
2020-09-29 |
2023-08-13 |
Not clear |
| Sheyda Sofizadeh, Henrik Imberg, Arndís F Ólafsdóttir, Magnus Ekelund, Sofia Dahlqvist, Irl Hirsch, Karin Filipsson, Bo Ahrén, Stefan Sjöberg, Jaako Tuomilehto, Marcus Lin. Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 10. issue 6. 2020-09-29. PMID:31564026. |
the effects of the glp-1 analogue liraglutide on time in hypoglycaemia, time in hyperglycaemia, and time in range for type 2 diabetes patients initially treated with multiple daily insulin injections (mdi) were investigated. |
2020-09-29 |
2023-08-13 |
Not clear |
| Miaad Bader, Yazhou Li, David Tweedie, Nathan A Shlobin, Adi Bernstein, Vardit Rubovitch, Luis B Tovar-Y-Romo, Richard D DiMarchi, Barry J Hoffer, Nigel H Greig, Chaim G Pic. Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. Frontiers in cell and developmental biology. vol 7. 2020-09-29. PMID:31998717. |
the incretins glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are gastrointestinal hormones that induce glucose-dependent insulin secretion, promote β-cell proliferation, and enhance resistance to apoptosis. |
2020-09-29 |
2023-08-13 |
mouse |
| Weizheng Li, Pengzhou Li, Rao Li, Zhaomei Yu, Xulong Sun, Guangnian Ji, Xiangwu Yang, Liyong Zhu, Shaihong Zh. DNA and cell biology. vol 39. issue 9. 2020-09-29. PMID:32721233. |
however, the single-nucleotide polymorphisms (snps) of glp-1 receptor (glp1r) impair receptor function, subsequently affecting β cell insulin secretion function, ultimately affecting the efficacy of rygb. |
2020-09-29 |
2023-08-13 |
Not clear |
| Masahiko Miyagi, Hiroshi Uchino, Naoki Kumashiro, Mariko Higa, Koki Shin, Makiko Sasamoto, Hiroji Kitazato, Motoyuki Tamaki, Munehide Matsuhisa, Takahisa Hiros. Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 5. 2020-09-28. PMID:30121725. |
up-titration strategy after dpp-4 inhibitor-based oral therapy for type 2 diabetes: a randomized controlled trial shifting to a single-dose glp-1 enhancer versus adding a variable basal insulin algorithm. |
2020-09-28 |
2023-08-13 |
Not clear |
| Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Revirieg. A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 10. issue 1. 2020-09-28. PMID:30506340. |
glp-1 ras augment insulin secretion and suppress glucagon release via the stimulation of glp-1 receptors. |
2020-09-28 |
2023-08-13 |
Not clear |
| Lili Liu, Zhuo Shao, Ying Xia, Jiabi Qin, Yang Xiao, Zhiguang Zhou, Zubing Me. Incretin-based therapies for patients with type 1 diabetes: a meta-analysis. Endocrine connections. vol 8. issue 3. 2020-09-28. PMID:30694794. |
combined treatment with an incretin-based drug, such as a glucagon-like peptide 1 receptor agonist (glp-1 ra) or a dipeptidyl peptidase-4 (dpp-4) inhibitor, and basal insulin is a new strategy for improving glucose control in type 1 diabetes mellitus (t1dm). |
2020-09-28 |
2023-08-13 |
Not clear |